SCHEMBL6225217

SCHEMBL6225217

CSc1c(C)[nH]c2cc(F)ccc2c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ KDM4E B2RXH2 4/20 0.49
▸ PTGS1 P23219 2/20 0.46
▸ PTGS2 P35354 2/20 0.46
▸ FEN1 P39748 1/20 0.45
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ PARP1 P09874 1/20 0.44
▸ SLC2A1 P11166 1/20 0.42
▸ DAO P14920 1/20 0.41
▸ TNKS2 Q9H2K2 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ KIF11 P52732 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9869161 0.81 KDM4E (0.53) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL9868548 0.79 SMN1; SMN2 (0.43) LMNASMN1; SMN2KDM4EPTGS1PTGS2
SCHEMBL10481523 0.78 KDM4E (0.52) LMNAKDM4EPTGS1PTGS2FEN1
SCHEMBL7159367 0.75 PTGS1 (0.46) KDM4EPTGS1PTGS2FEN1MEN1
SCHEMBL6224556 0.73 MEN1 (0.43) LMNAKDM4EPTGS1PTGS2FEN1
SCHEMBL6227910 0.73 MEN1 (0.43) LMNAKDM4EPTGS1PTGS2FEN1
SCHEMBL6229784 0.73 MEN1 (0.43) LMNAKDM4EPTGS1PTGS2FEN1
SCHEMBL870205 0.72 KDM4E (0.65) LMNASMN1; SMN2KDM4EFEN1MEN1
SCHEMBL19481419 0.72 AHR (0.52) LMNAKDM4EPTGS1PTGS2FEN1
SCHEMBL18949683 0.71 KIF11 (0.49) LMNAKDM4EPTGS1PTGS2FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1446120-A4 STEREOSPECIFIC ENRICHMENT OF HETEROCYCLIC ENANTIOMERS R T ALAMO VENTURES I LLC (US) 2005-01-26 — — EP claimed
EP-1446120-A1 STEREOSPECIFIC ENRICHMENT OF HETEROCYCLIC ENANTIOMERS R.T. Alamo Ventures I, LLC (US) 2004-08-18 — — EP claimed
WO-2003035071-A1 STEREOSPECIFIC ENRICHMENT OF HETEROCYCLIC ENANTIOMERS R.T. ALAMO VENTURES I, LLC (US) 2003-05-01 — — WO claimed
JP-2002522388-A — — 2002-07-23 — — JP claimed
EP-1107759-A1 PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION Basf Corporation (US) 2001-06-20 — — EP claimed
WO-2000007595-A1 PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION BASF CORPORATION (US) 2000-02-17 — — WO claimed
EP-1446120-A4 STEREOSPECIFIC ENRICHMENT OF HETEROCYCLIC ENANTIOMERS R T ALAMO VENTURES I LLC (US) 2005-01-26 — — EP disclosed
EP-1446120-A1 STEREOSPECIFIC ENRICHMENT OF HETEROCYCLIC ENANTIOMERS R.T. Alamo Ventures I, LLC (US) 2004-08-18 — — EP disclosed
WO-2003035071-A1 STEREOSPECIFIC ENRICHMENT OF HETEROCYCLIC ENANTIOMERS R.T. ALAMO VENTURES I, LLC (US) 2003-05-01 — — WO disclosed
EP-1107759-A1 PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION Basf Corporation (US) 2001-06-20 — — EP disclosed
WO-2000007595-A1 PYRIDINONES FOR THE TREATMENT OF SEXUAL DYSFUNCTION BASF CORPORATION (US) 2000-02-17 — — WO disclosed
Send feedback